Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Change in Accured Expenses (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Change in Accured Expenses readings, the most recent being $156000.0 for Q2 2025.

  • On a quarterly basis, Change in Accured Expenses rose 136.36% to $156000.0 in Q2 2025 year-over-year; TTM through Dec 2025 was -$57000.0, a N/A change, with the full-year FY2025 number at -$57000.0, changed N/A from a year prior.
  • Change in Accured Expenses hit $156000.0 in Q2 2025 for Arcadia Biosciences, up from -$213000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $1.1 million in Q2 2021 to a low of -$1.1 million in Q3 2021.
  • Median Change in Accured Expenses over the past 5 years was -$73000.0 (2021), compared with a mean of -$52500.0.
  • The widest YoY moves for Change in Accured Expenses: up 340.21% in 2022, down 6700.0% in 2022.
  • Arcadia Biosciences' Change in Accured Expenses stood at -$373000.0 in 2021, then soared by 340.21% to $896000.0 in 2022, then plummeted by 124.78% to -$222000.0 in 2023, then surged by 104.95% to $11000.0 in 2024, then soared by 1318.18% to $156000.0 in 2025.
  • The last three reported values for Change in Accured Expenses were $156000.0 (Q2 2025), -$213000.0 (Q1 2025), and $11000.0 (Q4 2024) per Business Quant data.